Clinical Activity and Safety of IDH2 Inhibitor Enasidenib (AG-221) in IDH2-Mutant Relapsed/Refractory AML

June 2-6, 2017; Chicago, Illinois
Enasidenib was associated with durable CRs and low rates of treatment-related grade 3/4 adverse events.
Format: Microsoft PowerPoint (.ppt)
File Size: 264 KB
Released: June 12, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings